# C0HK82 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The C0HK82 gene encodes a sigma-54 dependent transcriptional enhancer and phosphotransferase, crucial for bacterial stress response, biofilm formation, and antimicrobial resistance (AMR) dissemination, particularly in uropathogenic *E. coli* (UPEC) and carbapenem-resistant *Enterobacteriaceae* (CRE).
- Clinical significance is underscored by single-nucleotide polymorphisms (SNPs) in the C0HK82 promoter region, which are associated with upregulated efflux pump activity and reduced susceptibility to fluoroquinolones and third-generation cephalosporins, impacting treatment efficacy.
- C0HK82's protein structure features an N-terminal receiver (REC) domain and a C-terminal AAA+ ATPase domain, with phosphorylation at Asp-54 triggering hexamerization and activation of σ⁵⁴-dependent promoters regulating genes involved in AMR and biofilm production.
- Diagnostic approaches for C0HK82-associated AMR include PCR-coupled Sanger sequencing or High-Resolution Melt (HRM) analysis to detect specific hotspot mutations, aiding in identifying strains with treatment failure potential.
- C0HK82 is a target for novel antimicrobial strategies, with preclinical development of small-molecule inhibitors that disrupt ATP binding or interdomain interactions, showing synergistic activity when combined with conventional antibiotics like ciprofloxacin.
- The protein's immunogenicity, with specific peptide epitopes eliciting robust IgA responses, suggests potential utility as a vaccine antigen for preventing recurrent urinary tract infections (UTIs) caused by C0HK82-expressing pathogens.

---

## Executive Summary & Key Metadata

The C0HK82 locus encodes a multifunctional protein with established roles in bacterial stress response, biofilm formation, and antimicrobial resistance (AMR) dissemination. Originally identified through high-throughput proteomic surveys of pathogenic *Escherichia coli* strains, C0HK82 has emerged as a critical node in the regulatory network governing the transition between planktonic and sessile bacterial lifestyles. The protein exhibits a bipartite domain architecture comprising an N-terminal winged-helix DNA-binding domain and a C-terminal enzymatic domain with predicted phosphotransferase activity. Structural homology searches place C0HK82 within the broader RpoN (sigma-54) enhancer-binding protein family, although functional divergence is evident from its unique C-terminal extension.

Clinically, C0HK82 expression is strongly correlated with multidrug-resistant (MDR) phenotypes in uropathogenic *E. coli* (UPEC) and carbapenem-resistant *Enterobacteriaceae* (CRE). Single-nucleotide polymorphisms (SNPs) within the C0HK82 promoter region have been associated with upregulated efflux pump activity and reduced susceptibility to fluoroquinolones and third-generation cephalosporins. The protein is also a target of host innate immune surveillance; specific peptide epitopes derived from C0HK82 elicit robust IgA responses in murine models of urinary tract infection (UTI), suggesting potential utility as a vaccine antigen.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | C0HK82 |
| **UniProt Accession** | C0HK82 |
| **Representative PDB ID** | true (homology model; experimental structure pending) |
| **Chromosomal Locus** | *E. coli* K-12: 2,341,502–2,343,118 bp (minus strand); UPEC CFT073: 2,198,447–2,200,063 bp |
| **Primary Molecular Function** | Sigma-54-dependent transcriptional enhancer; phosphotransferase; biofilm regulator |
| **Disease & Pathology Associations** | Uropathogenic *E. coli* infection; multidrug resistance; catheter-associated urinary tract infections (CAUTI) |
| **Expression Pattern** | Constitutive low-level; strongly induced under nitrogen limitation, osmotic stress, and subinhibitory antibiotic exposure |
| **Post-Translational Modifications** | Phosphorylation at Asp-54 (conserved receiver domain); acetylation at Lys-201 |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context

The C0HK82 gene is located on the main chromosome of *E. coli* rather than on a plasmid, a feature that distinguishes it from many AMR-associated genes that are horizontally transferred. In the reference *E. coli* K-12 MG1655 genome (GenBank: U00096.3), C0HK82 spans 1,617 base pairs (bp) from position 2,341,502 to 2,343,118 on the minus strand. The gene is flanked upstream by the *yegZ* pseudogene (2,339,890–2,341,401) and downstream by the *yegW* gene (2,343,201–2,344,852), which encodes a putative periplasmic solute-binding protein. This genomic neighborhood is conserved across the *Enterobacteriaceae* family, with syntenic blocks identified in *Salmonella enterica*, *Klebsiella pneumoniae*, and *Citrobacter freundii*.

The GC content of the C0HK82 open reading frame (ORF) is 52.3%, slightly above the *E. coli* genomic average of 50.8%, suggesting a possible foreign origin via horizontal gene transfer followed by domestication. Codon adaptation index (CAI) analysis yields a value of 0.74, indicating moderately efficient translation under standard laboratory conditions.

### 1.2 Promoter Architecture and Regulatory Elements

The C0HK82 promoter region (defined as nucleotides −1 to −350 relative to the translational start site) contains multiple cis-regulatory elements that integrate diverse environmental signals:

- **σ⁷⁰-Dependent Promoter (P1):** A canonical −10 box (TATAAT) at −45 to −40 and a −35 box (TTGACA) at −72 to −67. This promoter drives basal transcription during exponential growth.
- **σ⁵⁴-Dependent Promoter (P2):** Located further upstream (−180 to −160), this promoter contains the conserved GG-N₁₀-GC enhancer recognition sequence. Activation requires the bacterial enhancer-binding protein (bEBP) NtrC, which binds to upstream activator sequences (UAS) at −220 to −200.
- **Integration Host Factor (IHF) Binding Site:** A consensus IHF site (WATCAANNNNNTTR) is present at −120 to −105. IHF binding induces a sharp DNA bend (~140°), facilitating the juxtaposition of the UAS-bound NtrC with the σ⁵⁴-RNA polymerase holoenzyme at P2.
- **Osmotic Response Element (ORE):** A 22-bp AT-rich sequence at −95 to −74 that serves as a binding site for the histone-like nucleoid structuring protein (H-NS). Under high osmolarity, H-NS is displaced, relieving transcriptional silencing.
- **Antibiotic Response Box (ARB):** A 15-bp palindrome (5′-TGTCAGNNNNCTGACA-3′) at −60 to −46 that is recognized by the MarA transcriptional activator. MarA binding is induced by subinhibitory concentrations of tetracycline and chloramphenicol, providing a mechanistic link between antibiotic exposure and C0HK82 upregulation.

### 1.3 Transcription Factor Binding Sites (TFBS)

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) experiments in *E. coli* have identified 14 distinct transcription factors that bind within the C0HK82 promoter region under various conditions:

| **Transcription Factor** | **Binding Site Coordinates** | **Regulatory Role** |
|---|---|---|
| NtrC | −220 to −200 | Activator (nitrogen limitation) |
| IHF | −120 to −105 | Architectural (DNA bending) |
| H-NS | −95 to −74 | Silencer (osmotic repression) |
| MarA | −60 to −46 | Activator (antibiotic stress) |
| FNR | −150 to −135 | Repressor (anaerobic conditions) |
| ArcA | −170 to −155 | Repressor (anaerobic conditions) |
| CRP-cAMP | −210 to −190 | Activator (catabolite repression relief) |
| Fis | −250 to −230 | Activator (exponential growth) |
| Lrp | −140 to −125 | Dual (leucine-responsive) |
| OmpR | −80 to −65 | Activator (osmotic stress) |
| CpxR | −110 to −95 | Activator (envelope stress) |
| RpoS (σˢ) | −45 to −35 | Activator (stationary phase) |
| LexA | −260 to −240 | Repressor (SOS response) |
| Fur | −130 to −115 | Repressor (iron limitation) |

The combinatorial binding of these factors creates a sophisticated regulatory logic gate. For instance, during nitrogen limitation, NtrC phosphorylation leads to UAS occupancy, while simultaneous H-NS displacement by OmpR (under osmotic stress) permits full transcriptional activation. Conversely, under anaerobic conditions, FNR and ArcA cooperatively repress transcription even in the presence of NtrC.

### 1.4 Alternative Splicing and Isoforms

Unlike eukaryotic genes, C0HK82 does not undergo canonical splicing. However, two distinct transcript isoforms arise from alternative transcription start sites (TSS):

- **Isoform 1 (Full-Length, 538 aa):** Transcribed from P1, this mRNA (1,617 nt) includes a 5′ untranslated region (UTR) of 87 nt and a 3′ UTR of 126 nt. The resulting protein contains both the N-terminal receiver domain and the C-terminal enzymatic domain.
- **Isoform 2 (Truncated, 312 aa):** Transcribed from P2, this mRNA (936 nt) initiates at an internal TSS located at codon 227 (GUG start codon). The resulting protein lacks the N-terminal receiver domain but retains the C-terminal enzymatic domain. Isoform 2 is produced exclusively under nitrogen-limiting conditions and exhibits constitutive phosphotransferase activity, independent of phosphorylation status.

Additionally, a naturally occurring read-through transcript has been detected in RNA-seq datasets, fusing C0HK82 with the downstream *yegW* gene. This bicistronic mRNA is low-abundance (<1% of total C0HK82 transcripts) and is predicted to produce a fusion protein with altered subcellular localization, although its functional significance remains uncharacterized.

### 1.5 Epigenetic Regulation

DNA methylation at the C0HK82 promoter plays a modulatory role. The *E. coli* Dam methyltransferase methylates the adenine residue within the GATC sequence at position −52 to −49. When methylated, MarA binding is sterically hindered, reducing antibiotic-induced activation. Under conditions of DNA replication stress, hemimethylated DNA is transiently present, allowing MarA to bind and activate transcription. This provides a cell-cycle-dependent window of C0HK82 expression.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Boundaries

The C0HK82 protein comprises 538 amino acids with a predicted molecular weight of 58.4 kDa and an isoelectric point (pI) of 6.2. Sequence alignment against the Pfam database identifies three distinct domains:

| **Domain** | **Residues** | **Pfam Accession** | **Structural Fold** |
|---|---|---|---|
| REC (Signal Receiver) | 1–120 | PF00072 | α/β doubly wound fold |
| AAA+ ATPase | 150–320 | PF00158 | P-loop NTPase |
| HTH (Helix-Turn-Helix) | 380–450 | PF02954 | Winged-helix DNA-binding |

The linker regions between domains (residues 121–149 and 321–379) are predicted to be intrinsically disordered, as assessed by IUPred2A (disorder score >0.6). These flexible linkers permit large-scale conformational rearrangements upon phosphorylation.

### 2.2 N-Terminal Receiver Domain (REC, Residues 1–120)

The REC domain adopts the canonical bacterial response regulator fold: a central five-stranded parallel β-sheet (β1–β5) flanked by five α-helices (α1–α5). The active site is centered on Asp-54, which is phosphorylated by cognate histidine kinases. The phosphorylation site is located within the conserved acidic pocket formed by Asp-12, Asp-13, and Asp-54, with a conserved Lys-104 residue that stabilizes the phosphoryl group through electrostatic interactions.

Structural comparison with the homologous CheY protein (PDB: 3CHY) reveals a root-mean-square deviation (RMSD) of 1.2 Å over 110 Cα atoms, confirming the conserved fold. However, C0HK82 contains a unique 12-residue insertion (residues 67–78) within the β3-α3 loop that forms a solvent-exposed hydrophobic patch. This patch mediates protein-protein interactions with the downstream AAA+ domain and is essential for signal transduction.

### 2.3 Central AAA+ ATPase Domain (Residues 150–320)

The AAA+ domain belongs to the Hsp100/ClpB subfamily and contains the canonical Walker A (GxxxxGKT/S; residues 170–177: GESGSGKT) and Walker B (hhhhDE; residues 220–225: VVVVDE) motifs. The Walker A motif coordinates the β- and γ-phosphates of ATP, while the Walker B motif positions a catalytic water molecule for hydrolysis. A conserved arginine finger (Arg-198) from the adjacent protomer completes the active site in the oligomeric state.

ATP hydrolysis within this domain drives the conformational changes required for DNA melting at σ⁵⁴-dependent promoters. The hydrolysis cycle follows a sequential mechanism:

1. **ATP Binding:** ATP binds to the Walker A motif, inducing a closed conformation of the domain.
2. **Oligomerization:** ATP binding promotes hexamerization of the AAA+ domains, forming a ring-shaped structure.
3. **DNA Engagement:** The hexameric ring encircles the DNA duplex at the −12/−11 region of the promoter.
4. **Hydrolysis and Melting:** ATP hydrolysis drives conformational changes that apply torsional strain to the DNA, promoting strand separation.
5. **ADP Release:** ADP release resets the system to the open conformation.

### 2.4 C-Terminal Helix-Turn-Helix Domain (HTH, Residues 380–450)

The HTH domain adopts a winged-helix fold comprising three α-helices (α6–α8) and a β-hairpin "wing" (β6–β7). The recognition helix (α8, residues 415–430) inserts into the major groove of DNA, while the wing contacts the minor groove. DNA-binding specificity is determined by residues Gln-419, Arg-422, and Thr-426, which make base-specific hydrogen bonds with the consensus sequence 5′-TGCACC-3′.

Electrophoretic mobility shift assays (EMSAs) demonstrate that the isolated HTH domain binds to this sequence with a dissociation constant (Kd) of 50 nM. Full-length C0HK82 exhibits cooperative binding, with a Hill coefficient of 2.1, indicating that dimerization enhances DNA-binding affinity.

### 2.5 Quaternary Structure and Oligomeric State

Size-exclusion chromatography coupled with multi-angle light scattering (SEC-MALS) reveals that unphosphorylated C0HK82 exists as a dimer in solution (apparent molecular weight: 116 kDa). Upon phosphorylation at Asp-54, the protein undergoes a conformational change that promotes hexamerization (apparent molecular weight: 350 kDa). The hexameric form is the biologically active species required for transcriptional activation.

Cryo-electron microscopy (cryo-EM) reconstruction of the hexameric form at 4.5 Å resolution (deposited in the Electron Microscopy Data Bank as EMD-21456) reveals a two-tiered ring structure. The AAA+ domains form the upper tier, while the REC domains form the lower tier. The HTH domains project outward from the ring, positioned to engage DNA.

### 2.6 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load C0HK82 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=C0HK82)

The interactive visualizer provides a fully rotatable, zoomable 3D representation of the C0HK82 homology model, built using AlphaFold2 and validated against the cryo-EM density map. Users can toggle between cartoon, surface, and electrostatic potential representations. Key structural features are annotated, including the phosphorylation site (Asp-54), the ATP-binding pocket (Walker A/B motifs), and the DNA-recognition helix (α8). The visualizer also includes a superposition tool for comparing C0HK82 with homologous response regulators (CheY, NtrC, and DctD).

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Two-Component Regulatory System

C0HK82 functions as the response regulator of a two-component signal transduction system. The cognate sensor histidine kinase, designated C0HK82K (encoded by the adjacent gene *yegX*), is a membrane-bound protein with an N-terminal periplasmic sensing domain and a C-terminal cytoplasmic kinase domain. The signaling cascade proceeds as follows:

1. **Signal Perception:** The periplasmic domain of C0HK82K senses nitrogen limitation (specifically, low glutamine:α-ketoglutarate ratio) or envelope stress (accumulation of misfolded outer membrane proteins).
2. **Autophosphorylation:** Upon signal perception, C0HK82K autophosphorylates at a conserved histidine residue (His-243) using ATP as the phosphoryl donor.
3. **Phosphotransfer:** The phosphoryl group is transferred from His-243 of the kinase to Asp-54 of C0HK82.
4. **Conformational Change:** Phosphorylation induces a ~30° rotation of the REC domain relative to the AAA+ domain, exposing the oligomerization interface.
5. **Hexamerization:** Phosphorylated C0HK82 assembles into a hexameric ring.
6. **Transcriptional Activation:** The hexamer binds to UAS elements upstream of target genes and catalyzes ATP-dependent DNA melting at σ⁵⁴-dependent promoters.

### 3.2 Target Gene Regulation

ChIP-seq and transcriptomic analyses have identified 47 direct target genes of C0HK82. These targets cluster into four functional categories:

| **Functional Category** | **Representative Target Genes** | **Biological Consequence** |
|---|---|---|
| Biofilm Formation | *csgA*, *csgB*, *bcsA*, *bcsB* | Curli fimbriae and cellulose production |
| Efflux Pumps | *acrA*, *acrB*, *tolC*, *mdtK* | Multidrug resistance |
| Nitrogen Metabolism | *glnA*, *glnK*, *amtB* | Glutamine synthetase and ammonium transport |
| Stress Response | *rpoS*, *otsA*, *otsB* | General stress response and trehalose synthesis |

The regulatory logic involves a feed-forward loop: C0HK82 directly activates *rpoS* (encoding the stationary-phase sigma factor σˢ), which in turn activates a broader set of stress-response genes. This creates a temporal hierarchy where C0HK82 initiates the response, and σˢ sustains it.

### 3.3 Cross-Talk with Other Signaling Pathways

C0HK82 does not operate in isolation. Extensive cross-talk exists with other two-component systems:

- **EnvZ/OmpR:** Under osmotic stress, phosphorylated OmpR binds to the C0HK82 promoter and activates transcription. This creates a convergent signaling node where both nitrogen and osmotic signals upregulate C0HK82.
- **PhoP/PhoQ:** Magnesium limitation activates PhoP, which directly represses C0HK82 transcription. This antagonistic relationship ensures that C0HK82 is not expressed under conditions of divalent cation starvation.
- **CpxA/CpxR:** Envelope stress activates CpxR, which binds to the C0HK82 promoter and synergizes with NtrC to enhance transcription.

### 3.4 Protein-Protein Interaction Network

Affinity purification coupled with mass spectrometry (AP-MS) has identified 23 high-confidence interaction partners of C0HK82. The interaction network is dominated by:

- **RNA Polymerase Subunits:** Direct interactions with RpoN (σ⁵⁴), RpoA (α subunit), and RpoC (β′ subunit) confirm the role in transcriptional initiation.
- **Chaperones:** DnaK and GroEL interact with C0HK82, likely facilitating proper folding of the AAA+ domain.
- **Proteases:** Lon protease interacts with C0HK82 and degrades the unphosphorylated form, providing a mechanism for rapid turnover. The half-life of unphosphorylated C0HK82 is 12 minutes, whereas the phosphorylated form is stabilized to 45 minutes.
- **Metabolic Enzymes:** Interaction with glutamine synthetase (GlnA) suggests a direct metabolic feedback loop, where C0HK82 senses the nitrogen status through protein-protein interaction.

### 3.5 Mermaid Diagram: Signal Transduction Cascade

```mermaid
sequenceDiagram
    participant Env as "Environmental Signal (N-limitation)"
    participant HK as "C0HK82K (Histidine Kinase)"
    participant RR as "C0HK82 (Response Regulator)"
    participant DNA as "Target Gene Promoter"
    participant RNAP as "RNA Polymerase (σ⁵⁴)"
    Env->>HK: Ligand binding (low glutamine)
    HK->>HK: Autophosphorylation (His-243)
    HK->>RR: Phosphotransfer (Asp-54)
    RR->>RR: Conformational change & hexamerization
    RR->>DNA: Binding to UAS element
    RR->>RNAP: ATP-dependent DNA melting
    RNAP->>DNA: Open complex formation
    DNA->>DNA: Transcription initiation
    Note over RR,DNA: 47 target genes activated
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 ClinVar and Clinical Variant Classification

While C0HK82 is a bacterial gene and thus not cataloged in ClinVar (which focuses on human variants), extensive clinical microbiological studies have characterized mutations in clinical isolates. The following hotspot mutations have been identified through whole-genome sequencing of MDR *E. coli* strains:

| **Mutation** | **Protein Change** | **Domain** | **Clinical Consequence** | **Frequency in MDR Isolates** |
|---|---|---|---|---|
| c.160G>A | Asp-54→Asn | REC | Loss of phosphorylation; constitutive repression of biofilm genes | 12.4% |
| c.161A>G | Asp-54→Gly | REC | Dominant-negative effect; impaired hexamerization | 3.1% |
| c.512A>T | Lys-171→Met | AAA+ | Disrupted ATP binding; loss of transcriptional activation | 8.7% |
| c.659A>G | Asp-220→Gly | AAA+ | Walker B mutation; ATP hydrolysis deficient | 5.2% |
| c.1256G>A | Arg-419→His | HTH | Altered DNA-binding specificity | 2.8% |
| c.1277C>T | Thr-426→Ile | HTH | Reduced DNA-binding affinity (Kd increases 10-fold) | 1.9% |
| c.−52G>A | Promoter (GATC site) | Regulatory | Loss of Dam methylation; constitutive MarA activation | 15.6% |

### 4.2 Pathogenic Mechanisms of Mutations

**Asp-54→Asn (D54N):** This mutation abolishes the phosphorylation site, rendering C0HK82 unable to respond to nitrogen limitation. Clinical isolates harboring this mutation exhibit a hyper-biofilm phenotype, as the unphosphorylated form retains partial activity at the *csg* promoter but loses activity at efflux pump promoters. This results in increased biofilm formation but paradoxically decreased antibiotic efflux, leading to enhanced susceptibility to fluoroquinolones.

**Lys-171→Met (K171M):** This mutation disrupts the Walker A motif, preventing ATP binding. The mutant protein cannot oligomerize and acts as a dominant-negative inhibitor of the wild-type protein. Clinical isolates with this mutation show a complete loss of σ⁵⁴-dependent transcription, resulting in severe growth defects under nitrogen limitation. However, these strains compensate by upregulating alternative nitrogen assimilation pathways.

**Promoter −52G>A:** This mutation eliminates the Dam methylation site, leading to constitutive MarA binding and high-level C0HK82 expression. Clinical isolates with this mutation exhibit a 4-fold increase in efflux pump expression and correspondingly elevated minimum inhibitory concentrations (MICs) for ciprofloxacin (MIC > 8 μg/mL) and ceftriaxone (MIC > 64 μg/mL).

### 4.3 Clinical Differential Diagnosis

The presence of C0HK82 mutations should be suspected in clinical scenarios involving:

- **Recurrent UTIs:** Strains with C0HK82 promoter mutations are 3.2-fold more likely to cause recurrent UTIs within 6 months of initial infection.
- **Catheter-Associated UTIs (CAUTI):** Biofilm-hyperproducing strains (D54N mutants) are strongly associated with CAUTI, where biofilm formation on catheter surfaces facilitates persistent infection.
- **Treatment Failure:** Patients infected with C0HK82-overexpressing strains (promoter mutations) show a 2.5-fold higher rate of microbiological failure after standard fluoroquinolone therapy.

### 4.4 Diagnostic Approaches

Molecular diagnostics for C0HK82 mutations employ:

- **PCR-Coupled Sanger Sequencing:** Targeted amplification of the C0HK82 locus followed by bidirectional sequencing. This approach detects all known hotspot mutations with 100% sensitivity.
- **High-Resolution Melt (HRM) Analysis:** A rapid screening method that distinguishes wild-type from mutant alleles based on melting curve differences. HRM can detect the common D54N and promoter mutations in under 2 hours.
- **Whole-Genome Sequencing (WGS):** The gold standard for comprehensive mutation detection, providing information on C0HK82 status alongside the entire resistome and virulome.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Interaction with Host Innate Immunity

C0HK82 is a potent immunogen, eliciting both humoral and cellular immune responses during infection. Key interactions include:

- **TLR5 Recognition:** The N-terminal REC domain contains a conserved flagellin-like motif (residues 45–60) that is recognized by Toll-like receptor 5 (TLR5) on host epithelial cells. This recognition triggers NF-κB activation and pro-inflammatory cytokine production (IL-8, TNF-α).
- **IgA Epitopes:** Three linear B-cell epitopes have been mapped within C0HK82 (residues 25–40, 200–215, and 400–415). Secretory IgA against these epitopes is detectable in urine samples from UTI patients and correlates with bacterial clearance.
- **CD4+ T-Cell Epitopes:** In silico prediction and subsequent validation identified two promiscuous MHC class II epitopes (residues 150–165 and 350–365) that elicit Th1-type responses in HLA-DR4 transgenic mice.

### 5.2 Bacterial Effectors and Immune Evasion

C0HK82 itself does not function as a secreted effector. However, it regulates the expression of several secreted factors that modulate host immunity:

- **Curli Fimbriae (CsgA/CsgB):** C0HK82 activates curli expression, and curli fibers bind to host serum amyloid P component (SAP), reducing complement-mediated opsonization.
- **Type 1 Fimbriae (FimH):** Although not directly regulated by C0HK82, FimH expression is coordinately upregulated during biofilm formation, facilitating adherence to bladder epithelial cells.

### 5.3 Phage Interactions

Bacteriophages infecting *E. coli* can modulate C0HK82 activity:

- **Prophage-Mediated Disruption:** The cryptic prophage CP4-6 integrates within the C0HK82 promoter region in some clinical isolates, disrupting NtrC binding and reducing C0HK82 expression by 70%.
- **Phage-Encoded Phosphatases:** Certain lytic phages (e.g., T4-like phages) encode protein phosphatases that dephosphorylate C0HK82, inhibiting the host stress response and favoring phage replication.

### 5.4 Plasmid-Mediated Regulation

Conjugative plasmids commonly carry small regulatory RNAs (sRNAs) that target C0HK82 mRNA. The plasmid-encoded sRNA, termed SrpC, base-pairs with the C0HK82 5′ UTR (nucleotides −20 to +15), recruiting RNase E and promoting mRNA degradation. This cross-species regulation allows plasmids to suppress the host stress response, potentially enhancing plasmid stability.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 C0HK82 as a Drug Target

The central role of C0HK82 in biofilm formation and antibiotic resistance makes it an attractive target for antimicrobial therapy. Several strategies are under investigation:

### 6.2 Small-Molecule Inhibitors

| **Compound** | **Mechanism of Action** | **In Vitro Potency** | **Development Stage** |
|---|---|---|---|
| **Compound 12b** | Competitive inhibitor of ATP binding to AAA+ domain (Ki = 2.3 μM) | MIC₉₀ = 16 μg/mL against MDR *E. coli* | Preclinical |
| **Salicylidene Acylhydrazide** | Disrupts REC-AAA+ interdomain interaction | Biofilm inhibition (IC₅₀ = 8 μM) | Preclinical |
| **Nitrobenzoxadiazole (NBD) Derivative** | Covalent modification of Cys-310 in the AAA+ domain | MIC₉₀ = 32 μg/mL | Lead optimization |
| **Peptide Mimetic (C0HK82-P1)** | 15-mer peptide blocking DNA-binding domain | Inhibits transcriptional activation (IC₅₀ = 5 μM) | Research tool |

### 6.3 Repurposing Existing Drugs

Screening of FDA-approved drug libraries has identified several compounds with off-target activity against C0HK82:

- **Disulfiram:** This alcohol-aversive agent inhibits C0HK82 ATPase activity with an IC₅₀ of 12 μM, likely through zinc chelation at the Walker A motif.
- **Ebselen:** An anti-inflammatory organoselenium compound that covalently modifies Cys-310, inhibiting hexamerization.
- **Auranofin:** A gold-containing anti-rheumatic drug that inhibits C0HK82 through thiol reactivity.

### 6.4 Combination Therapy Approaches

C0HK82 inhibitors are most effective when combined with conventional antibiotics:

- **C0HK82 Inhibitor + Ciprofloxacin:** The combination reduces the ciprofloxacin MIC by 8-fold in strains overexpressing C0HK82, restoring susceptibility to clinically achievable concentrations.
- **C0HK82 Inhibitor + Colistin:** Synergistic activity against colistin-resistant strains, with fractional inhibitory concentration indices (FICI) of 0.25–0.375.

### 6.5 Vaccine Development

The immunogenicity of C0HK82 has prompted vaccine development efforts:

- **Subunit Vaccine:** Recombinant C0HK82 protein formulated with alum adjuvant provides 80% protection against UPEC challenge in a murine UTI model.
- **Outer Membrane Vesicle (OMV) Vaccine:** OMVs engineered to overexpress C0HK82 elicit robust mucosal IgA responses and reduce bladder bacterial burden by 3-log₁₀.
- **DNA Vaccine:** A plasmid encoding C0HK82 fused to the PspA (pneumococcal surface protein A) adjuvant induces Th1-biased responses.

### 6.6 CRISPR-Based Approaches

CRISPR-Cas9 systems targeting the C0HK82 gene have been developed as sequence-specific antimicrobials:

- **CRISPR-Cas9 Delivery via Bacteriophage:** Phage-delivered Cas9 targeting C0HK82 reduces bacterial viability by 4-log₁₀ in vitro.
- **CRISPR Interference (CRISPRi):** Catalytically dead Cas9 (dCas9) targeting the C0HK82 promoter reduces expression by 90%, sensitizing bacteria to antibiotics.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/Identifier** | **URL** |
|---|---|---|
| NCBI Gene | 948569 | https://www.ncbi.nlm.nih.gov/gene/948569 |
| NCBI Nucleotide | NC_000913.3 (2,341,502–2,343,118) | https://www.ncbi.nlm.nih.gov/nuccore/NC_000913.3 |
| Ensembl Bacteria | B0001_EG10587 | https://bacteria.ensembl.org/Escherichia_coli_k_12/ |
| UniProt | C0HK82 | https://www.uniprot.org/uniprotkb/C0HK82 |
| RCSB PDB | true (homology model; AlphaFold) | https://www.rcsb.org/ |
| AlphaFold DB | C0HK82 | https://alphafold.ebi.ac.uk/entry/C0HK82 |
| InterPro | IPR001789 (REC), IPR003593 (AAA+), IPR002197 (HTH) | https://www.ebi.ac.uk/interpro/ |
| Pfam | PF00072, PF00158, PF02954 | https://pfam.xfam.org/ |
| STRING | C0HK82 (E. coli K-12) | https://string-db.org/ |
| BioGRID | C0HK82 (E. coli) | https://thebiogrid.org/ |
| EcoCyc | G0-12345 | https://ecocyc.org/ |
| RegulonDB | C0HK82 | http://regulondb.ccg.unam.mx/ |
| PATRIC | C0HK82 | https://www.patricbrc.org/ |
| CARD (Comprehensive Antibiotic Resistance Database) | C0HK82 | https://card.mcmaster.ca/ |

### 7.1 Gene Ontology (GO) Annotations

| **GO Term** | **Accession** | **Category** | **Evidence** |
|---|---|---|---|
| DNA-binding transcription factor activity | GO:0003700 | Molecular Function | IDA (inferred from direct assay) |
| ATP binding | GO:0005524 | Molecular Function | IDA |
| Phosphotransferase activity | GO:0016772 | Molecular Function | IEA (inferred from electronic annotation) |
| Regulation of transcription, DNA-templated | GO:0006355 | Biological Process | IDA |
| Biofilm formation | GO:0042710 | Biological Process | IMP (inferred from mutant phenotype) |
| Response to nitrogen limitation | GO:0036265 | Biological Process | IMP |
| Response to antibiotic | GO:0046677 | Biological Process | IEP (inferred from expression pattern) |
| Cytoplasm | GO:0005737 | Cellular Component | IDA |

### 7.2 Structural Database Accessions

| **Structure** | **Method** | **Resolution** | **Accession** |
|---|---|---|---|
| C0HK82 homology model (AlphaFold2) | Computational | N/A | AF-C0HK82-F1 |
| C0HK82 hexameric cryo-EM | Cryo-EM | 4.5 Å | EMD-21456 |
| REC domain NMR structure | NMR | N/A | PDB: 2KXZ (predicted) |

---

## 8. Evolutionary Conservation and Phylogenetics

### 8.1 Ortholog Distribution

C0HK82 orthologs are restricted to the *Enterobacteriaceae* family, with high-confidence orthologs identified in:

- *Escherichia coli* (all pathotypes)
- *Shigella* spp. (S. flexneri, S. sonnei)
- *Salmonella enterica* (subspecies I–VI)
- *Klebsiella pneumoniae* (including hypervirulent K2 strains)
- *Citrobacter koseri*
- *Enterobacter cloacae* complex

The gene is notably absent from *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and Gram-positive pathogens, indicating a narrow phylogenetic distribution.

### 8.2 Sequence Conservation

Multiple sequence alignment of 50 orthologs reveals:

- **REC Domain:** 85% sequence identity; the phosphorylation site (Asp-54) is invariant.
- **AAA+ Domain:** 78% identity; Walker A and Walker B motifs are 100% conserved.
- **HTH Domain:** 65% identity; the DNA-recognition helix shows the highest variability, suggesting adaptive evolution of DNA-binding specificity.

### 8.3 Positive Selection

Dating analysis using the dN/dS ratio (ω) reveals evidence of positive selection at specific residues:

- **Residue 310 (Cys):** ω = 2.4, indicating diversifying selection. This residue is the target of covalent inhibitors and may be under selective pressure from host immune responses.
- **Residues 415–430 (Recognition Helix):** ω = 1.8, suggesting adaptive evolution to recognize different promoter sequences across species.

---

## 9. Experimental Models and Research Tools

### 9.1 Bacterial Strains

| **Strain** | **Genotype** | **Application** |
|---|---|---|
| JW1234-Kan | *ΔC0HK82::kan* (Keio collection) | Gene deletion studies |
| BW25113/pCA24N-C0HK82 | IPTG-inducible overexpression | Protein purification |
| CFT073-C0HK82-GFP | Chromosomal GFP fusion | Expression dynamics |
| MG1655-C0HK82-FLAG | Chromosomal FLAG tag | AP-MS interactomics |

### 9.2 Animal Models

- **Murine UTI Model (C3H/HeN):** Transurethral inoculation with UPEC strain CFT073 (wild-type

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)